Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

被引：0
作者：
Yu Yao
Huaping Yang
Bo Zhu
Song Wang
Jiaohui Pang
Xiaoying Wu
Yang Xu
Junli Zhang
Jinfeng Zhang
Qiuxiang Ou
Hui Tian
Zheng Zhao
机构：
[1] First Affiliated Hospital of Xi’an Jiaotong University,Department of Medical Oncology
[2] Central South University,Department of Respiratory Medicine, Xiangya Hospital
[3] First Affiliated Hospital of Xi’an Jiaotong University,Department of Respiratory and Critical Care Medicine
[4] Nanjing Geneseeq Technology Inc.,Geneseeq Research Institute
[5] Ningbo Medical Centre Lihuili Hospital,Department of Thoracic Surgery
[6] Shaanxi Cancer Hospital,undefined
来源：
Respiratory Research | / 24卷
关键词：
Tyrosine kinase domain; NSCLC; EGFR-TKI; Genomic profiling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 123 条
[1]  
Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[2]  
Miller KD(2015)Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors Cancer Discov 5 850-859
[3]  
Fuchs HE(2014)Comprehensive molecular profiling of lung adenocarcinoma Nature 511 543-550
[4]  
Jemal A(2009)Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 1667-1674
[5]  
Frampton GM(2017)MET in lung cancer: biomarker selection based on scientific rationale Mol Cancer Ther 16 555-565
[6]  
Ali SM(2020)Targeting MET dysregulation in cancer Cancer Discov 10 922-934
[7]  
Rosenzweig M(2017)Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping J Thorac Oncol 12 137-140
[8]  
Chmielecki J(2016)Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping J Thorac Oncol 11 1242-1245
[9]  
Lu X(2016)Acquired METD1228V mutation and resistance to MET inhibition in lung cancer Cancer Discov 6 1334-1341
[10]  
Bauer TM(2011)A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients Cancer Res 71 5255-5264
12345678910